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Abstract
Background: Many intravenous opiate users are infected 
with hepatitis C virus (HCV) but few are treated. Although 
this complies with various guidelines, virtually no published 
evidence supports such a recommendation.
Patients and Methods: In a multicenter study, HCV-infected 
patients in opiate maintenance treatment programs received 
interferon plus high- or low-dose ribavirin (1,000/1,200 mg 
or 600 mg). HIV-coinfected patients were not included. 
Endpoints were feasibility, efficacy, side effects, and reasons 
for dropout.
Results: Of the 420 patients who tested positive for HCV, 
27 (6%) were enrolled; 393 (94%) either failed to meet 
the inclusion criteria or refused treatment. Virologic end-
of-treatment response was achieved in 12/27 patients, and 
sustained response in 13/27 (48%). Response depended on 
viral genotype, not ribavirin dose. The two doses of ribavirin 
did not differ in their side effects.
Conclusion: In a small fraction of HCV-infected intravenous 
drug users in an opiate maintenance treatment program, 
antiviral therapy was feasible, safe, and effective. The 
success rate was comparable to that achieved in controlled 
studies that excluded drug users.   
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Introduction
Hepatitis C virus (HCV) infection causes chronic hepati-
tis in approximately 85% of those infected, up to 20% of 
whom develop cirrhosis as a late sequela [1–3].  Antiviral 
therapy with standard or pegylated interferon-alpha plus 
different doses of ribavirin achieves sustained virus elimi-
nation in many cases depending on viral genotype [4–8]. 
HCV infection is particularly common in intravenous drug 
users. The estimated prevalence is between 60% and near 
100%, depending on risk behavior and duration of drug use 
[9–11]. Yet various national and international guidelines 
and consensus recommendations have excluded drug users 
from anti-HCV therapy [12, 13]. The reasons, disputed by 
some [14], are the following [15]:
• Inadequate compliance by drug users with HCV therapy
• High rate of (mainly psychological) side effects
• High risk of reinfection
• Coinfection with hepatitis B or HIV.
• A proposed alternative is to treat HCV infection only af-
ter the drug user has entered successful addiction therapy 
[16]. To our knowledge, however, only interim data on HCV 
treatment during opiate maintenance have been published 
[17].
We conducted a multicenter study of anti-HCV therapy 
with interferon alpha-2a plus ribavirin in drug users on opi-
ate maintenance treatment in Switzerland. The main objec-
tives were to document the reasons for nontreatment, and 
to determine the feasibility, efficacy, and safety of HCV 
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treatment in an opiate maintenance treatment  program. A 
secondary objective was to compare the side effects and ef-
ficacy of high- versus low-dose ribavirin.
Patients and Methods
Centers and Screening
Five centers took part in the study: two Zurich Opiate Consump-
tion Centers (Zürcher Opiat-Konsumlokal [ZOKL]), the ZOKL1 
and ZOKL2 drug clinics, operated by the Working Group for 
Low-Risk Drug Use (Arbeitsgemeinschaft für risikoarmen Um-
gang mit Drogen [ARUD-Zürich]); Drop-in Zurich; the St. Gallen 
Cantonal Hospital methadone maintenance unit; and a commu-
nity practice (PS, Lucerne). The centers offer two forms of opiate 
maintenance: methadone, with a low threshold for same-day entry 
(evidence of dependence and claiming two previous withdrawal 
attempts), and heroin, with high-threshold criteria (maintenance 
dependent on mandatory weekly consultation). At any one time 
the five centers maintain some 800 patients on methadone and 
100 on heroin.
HCV antibody testing was offered, and in most cases per-
formed, when patients entered the opiate substitution program. 
Screening for participation in this study was begun not before ad-
herence to opiate mainenance was achieved. None of the patients 
had signs or symptoms suggesting acute HCV infection during the 
screening phase.
The study was approved by the local institutional review 
board and the patients provided their informed written consent.
Inclusion and Exclusion Criteria
The inclusion criteria were age over 18 years, anti-HCV seroposi-
tivity, ≥ 50% elevation of transaminases for at least 6 months, pos-
itive HCV RNA, written informed consent, hemoglobin > 13 g/dl 
(women: > 12 g/dl), normal blood glucose or hemoglobin HbA1 
≤ 8.5%, and regular eye examination in diabetics. The exclusion 
criteria were pregnancy, lactation, intention to become pregnant 
within 1 year, hemochromatosis, autoimmune hepatitis, hyper-
thyroidism, life expectancy < 1 year, symptomatic cardiovascular 
disease, hepatitis B surface antigen positivity, liver disease due 
to causes other than HCV, other serious disease, HIV infection, 
creatinine > 150 µmol/l, leukocytes < 2.5 × 103/µl, neutrophils 
< 1.5 ×103/µl, platelets < 70 ×103/µl, cytostatic chemotherapy, an-
tiviral therapy in the previous 6 months, sexual activity in either 
sex without adequate contraception, use of a new drug in the pre-
vious 6 months, concomitant disease with possible morbidity or 
mortality during the study, past or ongoing serious neurological 
disease, uncontrolled psychiatric disease, or any other condition 
which, in the investigators’ opinion, could interfere with analysis 
of the study endpoints.
Treatment
Antiviral therapy comprised interferon alpha-2a 6 MU sc daily 
for 28 days, then thrice weekly for another 5 or 11 months (virus 
genotypes 2 and 3, and 1 and 4, respectively), combined through-
out the study with ribavirin, to which patients were randomized 
at a high or low dose (1,000/1,200 mg depending on body weight, 
and 600 mg, respectively). 
Endpoints
Clinical visits and laboratory investigations were performed 2 and 
4 weeks after the start of treatment, then monthly to the end of 
treatment, with an end of study visit 6 months after completing 
treatment. Virologic efficacy was assessed at 4 weeks, 28 weeks 
(end of treatment for virus types 2 and 3), 52 weeks (end of treat-
ment for virus types 1 and 4), and 6 months after completing treat-
ment (also after dropout). Subsidiary endpoints were side effects, 
which were WHO-graded, dose reductions, treatment interrup-
tions, and dropouts. HCV PCR was measured using COBAS® 
Amplicor® Monitor HCV RNS 2.0 (Hoffmann-La Roche, Basel, 
Switzerland), HCV genotyping was performed using INNO-Lipa 
HCV II (Bayer HealthCare Diagnostika, Fernwald, Germany). 
    
Statistics
In the intention-to-treat (ITT) analysis, differences in side effects 
and efficacy between the high and low doses of ribavirin were as-
sessed using the ² or Fisher’s exact test, and those in time on treat-
ment using the log rank test. The 95% confidence intervals (CI) of 
proportions were calculated as the proportion ± 2 standard errors.
Results
Enrollment and Patient Characteristics
Four centers screened and tested all patients routinely for 
HCV; of the 420 who were seropositive (seroprevalence: 
47%), 27 (6.4%; CI: 3.4%–8.4%) agreed to take part in 
the study (Table 1). An additional patient was included by 
the community practice center. Of the total 28 included pa-
tients, one female patient was excluded before randomiza-
tion due to lack of health insurance coverage.
M. Huber et al.   HCV Treatment in Opiate Maintenance 
26 Infection 33 · 2005 · No. 1 © URBAN & VOGEL
Reasons   N (%)
Patients attending opiate maintenance program 900a
   Methadone maintenance 800a
   Heroin maintenance 100a
Patients with positive HCV serology 420
Patients asked for study participation 420 (100)
   Included  27 (6.4)
   Excluded  393 (93.6)
Reasons for exclusion  571 (100)b
   Protocol exclusion criteria   459 (80.4)
     Normal liver enzymes (ALT)  153 (26.8)
     HIV coinfection    67 (11.7)
     Undetectable HCV (HCV PCR)    57 (10.0)
     Poor attendance in opiate treatment program  47 (8.2)
     Psychiatric reasons  43 (7.5)
     Alcohol consumption > 50 g/d  39 (6.9)
     Irregular opiate issue  28 (4.9)
     Other (incl. HBs antigen positivity)  25 (4.8)
  Patient refusal    112 (19.6)b
     Afraid of side effects  33 (5.8)
     Dislike of blood collection  30 (5.6)
     Appointments too frequent   18 (3.6)
     Unconvinced by necessity of treatment  11 (1.9)
     Dropout from maintenance program  10 (1.8)
     Receiving antiviral therapy elsewhere    7 (1.3)
     Other (incl. HBs antigen positive)    3 (0.5)
a Estimated average (due to fluctuation in the opiate mainte-
nance population); b mean 1.45 reasons per patient
Table 1
Reasons for nonparticipation in the study.
sons are shown in table 1. The detailed reasons have been 
published elsewhere [18].
The population, mean age 32 (20–42) years, comprised 
20 men (74%) and seven women (26%). The maintenance 
opiate was methadone in 23 cases, and heroin in the re-
mainder. 12 patients each (44.5%) were infected with virus 
genotypes 1 and 2/3, and three (11%) with genotype 4. 11 
patients were randomized to the high dose of ribavirin, and 
16 to the low dose; these groups did not differ significantly 
in age, gender or viral genotype (Table 2).
17 patients (63%) completed the study, including 
nine (33.3%) with no protocol violation. Eight patients 
(30%) experienced intermittent treatment interruptions 
or changes in dose due to side effects. The ten dropouts 
(37%) were due primarily to side effects (n = 6) or treat-
ment failure (n = 3) (Table 3).
Side Effects
Frequent WHO grade 2 to 4 side effects were flu-like 
syndrome (20/27), gastrointestinal disturbances (10/27), 
alopecia (7/27), anemia (5/27), granulocytopenia (5/27), 
and depression (4/27). Frequencies of side effects did not 
differ significantly between the two ribavirin dose groups 
(Table 4). 
The mean of the maximal hemoglobin decline in com-
parison to baseline levels  was 2.33 g/dl in the ribavirin 
high-dose group, and 2.1 g/dl in the low-dose group, re-
spectively (not significant; 95 % confidence interval of the 
difference  -1.23 to +0.78 g/dl). 
Only 4/11 patients in the high-dose group and 5/16 in 
the low-dose group managed to undergo therapy without a 
reduction in dose, interruption in treatment, or withdrawal 
from the study. Of the six dropouts due to side effects, 
three were due to granulocytopenia, two to psychological 
reasons, and one to gastrointestinal disturbances. In two of 
these dropouts, HCV was still undetectable 6 months after 
discontinuing therapy despite the short treatment period 
(12 and 31 days). 
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The reasons for nonparticipation totaled 571: 459 
(80.4%) were dictated by the protocol (inclusion/exclusion 
criteria), and 112 (19.6%) by patient choice. The major rea-
 Interferon +  Interferon +
Results ribavirin ribavirin P-value
 1000/1200 mg  600 mg
Treated patients 11 (100)  16 (100)
Study completers 7 (64) 10 (62) NS
6-month follow-upa 9 (82) 13 (81) NS
Protocol compliance
   No violation 4 (36)  5 (31) NS
   Violation 7 (64) 11 (69) NS
Dropout 4 (36)  6 (37) NS
   Virologic failure 2 (18) 1 (6) NS
   Side effects 2 (18)  4 (25) NS
   Patient choice 0 1 (6) NS
Virologic response 
(undetectable HCV RNA)
   4 weeks 8 (73) 10 (62) NS
   End of treatment   6 (54.6)     6 (37.5) NS
   Sustained at 6-month 
   follow-up   6 (54.6)     7 (43.7) NS
Virologic response of HCV 
genotype 1 or 4b
   Total patients, both arms                   15 (100)
   4 weeks                                 10 (67)
   End of treatment (52 weeks)                3 (20)
   Sustained at 6-month follow-up           3 (20)
Virologic response of HCV 
genotype 2 or 3a
   Total patients, both arms                   12 (100)  NS
   4 weeks                                            8 (67)  NS
   End of treatment (24 weeks)                9 (75)      0.014c
   Sustained at 6-month follow-up          10 (83)           < 0.01c
a Some 6-month values followed dropout; b  the small group sizes 
prevented separate high- versus low-dose analysis; c versus types 
1 and 4.
Table 3
Treatment results – n (%).
 Interferon + ribavirin   Interferon + ribavirin 
 1,000/1,200 mg 600 mg
Patients (n) 11 16
   Males (n) 8 12
Body weight (mean, kg) 71.3 71.5
Opiate maintenance
   Methadone 9 14
   Heroin 2 2
HCV genotype
   1 or 4 6 9
   2 or 3 5 7
a All intergroup comparisons: no significant differences.
Table 2
Patient characteristics at baselinea.
Characteristics
 Interferon +  Interferon +
 ribavirin ribavirin P-
 1,000/1,200 mg  600 mg value
Patients n (%) 11 (100) 16 (100)
Side effects (n)
   All 40 57 NS
     Anemia (< 10 g/dl)* 2 3 NS
     Leukopenia (< 800) 1 2 NS
     Thrombocytopenia  0 0 NS
     Flu-like syndrome 10 11 NS
     Pharyngitis 1 1 NS
     Dizziness 1 1 NS
     Depression 1 3 0.06
     Alopecia 3 5 NS
Table 4
WHO side effects grades 2 to 4.
Response Rates
In the ITT analysis, at 4 weeks, 18 patients (67%) were 
HCV PCR negative; differences in this respect between the 
high and low doses of ribavirin, and between virus geno-
types 2 or 3 and 1 or 4, were nonsignificant. At the end of 
treatment, 12 patients (44%) had undetectable HCV RNA 
by PCR (some end-of-treatment PCR missing in cases of 
early treatment interruption). Six months after complet-
ing therapy, this proportion had increased to 13 patients 
(48%; 95% CI: 29–67%). They comprised 6/11 (54.6%) in 
the high-dose ribavirin group, and 7/16 (43.8%) in the low-
dose group (not significant). Conversely, at this time, the 
response rates of the group with viral genotype 1 or 4 (3/15 
patients; 20%) differed from those with genotype 2 or 3 
(9/12 patients; 75%; p = 0.014) (Table 3).
Discussion
This study included only a small fraction, 27/420 (6%), of 
drug users in opiate maintenance programs who were sero-
positive for HCV. Nevertheless, in this setting, antiviral ther-
apy with interferon plus ribavirin proved feasible and safe. 
Efficacy, measured by sustained virus elimination, was 47% 
across all virus genotypes, i.e. comparable to that achieved 
using the same therapy in studies requiring cessation of opi-
ate use [5, 7]. Ribavirin dose had no impact on side effect fre-
quency or virologic success. Conversely patients with virus 
genotypes 2 and 3 had a significantly higher response rate 
(75%) than those with genotypes 1 and 4 (20%).
Side effects were common in this study, causing drop-
out in six patients and dose adjustment or treatment inter-
ruption in a further eight. The most frequent were flu-like 
syndrome, gastrointestinal disturbances, alopecia, anemia 
and granulocytopenia, and depression. Unexpectedly, fre-
quency did not differ between the high and low doses of 
ribavirin, but the sample size was possibly too small to ob-
serve differences.
Side effects were readily differentiated from opiate 
effects or symptoms associated with opiate withdrawal. 
The antiviral therapy caused no substantial changes in the 
opiate maintenance doses. Thus, although blood levels 
were not measured, pharmacologic interaction appears 
unlikely.
A strength of the study is that, to our knowledge, it is 
the first to report HCV treatment of drug users in an opi-
ate maintenance treatment program, along with rates of 
sustained viral elimination. Antiviral therapy proved fea-
sible, safe, and effective. It achieved a success rate similar 
to that in nondrug users. The opiate maintenance setting 
with regular, frequent contact encouraged good compli-
ance in patients normally considered as difficult to treat. 
Patients received their medication with each opiate issue, 
namely once to seven times weekly under staff supervision, 
the rest being take-home doses. Interferon injections were 
given at the treatment centers on patient request. Concom-
itant intravenous drug use caused no dropouts from opiate 
maintenance or antiviral treatment.
The study’s main weakness is its small population. 
Even so, the quality of the data suggests that drug users in 
a stable opiate maintenance setting can be treated for HCV 
as successfully as other patient groups, assuming compli-
ance with the inclusion and exclusion criteria. A further 
weakness is that we did not base the indication for antiviral 
therapy on liver biopsy.
The study data show that only a tiny fraction of the 
maintained opiate users qualified for HCV treatment. No 
HCV serology was available in approximately half the pa-
tients attending the opiate treatment centers, for reasons 
that can only be guessed at. Perhaps blood was not taken 
because patients did not remain in the opiate substitution 
program long enough or because their veins were difficult 
to puncture due to injury associated with their former in-
travenous drug use. Of the 420 who were seropositive for 
HCV, only 27 were ultimately treated. Of the reasons for 
nontreatment, 80% were dictated by the protocol, with 
physical reasons (HIV coinfection, negative HCV PCR, 
normal enzymes) far outnumbering psychiatric or addic-
tion-associated reasons (poor attendance, irregular main-
tenance opiate issue, serious psychiatric comorbidity, alco-
holism, benzodiazepine abuse, etc.).
We could not answer some important questions which 
need to be addressed in future studies, e.g. how often an-
tiviral therapy might be recommended in HCV-infected 
drug users based on the biopsy histology, how frequent is 
HCV reinfection, and how education after treatment im-
pacts reinfection risk behavior. Future studies will need 
to determine whether the pegylated interferons improve 
results in these patients too.
In summary, the study shows that HCV infection can 
be treated in a small proportion of drug users, irrespective 
of possible concomitant intravenous drug use, provided 
they regularly attend an opiate maintenance program and 
restrict their alcohol consumption, and provided the drug 
center possess the requisite know-how. Provided also that 
the contraindications are complied with, it appears unjus-
tified to withhold HCV therapy on principle from drug 
users who are not yet fully abstinent. Further studies are 
required in larger populations using pegylated interferons 
and ribavirin doses adjusted to body weight. The inclusion 
and exclusion criteria could also be relaxed, in particular 
to incorporate the HIV-coinfected patients who were ex-
cluded in the present study.
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